News & Media

Take a closer look at what we’re doing across Teva worldwide

Our latest news

Teva to Present at the BofA Securities Health Care Conference

Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Teva Releases Q1 2026 Aide Memoire

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
See all news items

Discover the world of Teva

Follow our latest feature stories with news and views from across our global organization

Discover more

Media Resources

at the office

Media Inquiries

Contact our corporate communications.
Learn more

Media Kit

Files and resources for media use only
Download Teva Media Kit

Financial Reports

View Teva financial news on our global website.
Learn more

Connect with us

Teva Social Media Guidelines.
Learn more